AAAAAA
Results: 1-25/31
Authors:
Sparidans, RW
Rosing, H
Hillebrand, MJX
Lopez-Lazaro, L
Jimeno, JM
Manzanares, I
van Kesteren, C
Cvitkovic, E
van Oosterom, AT
Schellens, JHM
Beijnen, JH
Citation: Rw. Sparidans et al., Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man, ANTI-CANC D, 12(8), 2001, pp. 653-666
Authors:
Delaloge, S
Yovine, A
Taamma, A
Riofrio, M
Brain, E
Raymond, E
Cottu, P
Goldwasser, F
Jimeno, J
Misset, JL
Marty, M
Cvitkovic, E
Citation: S. Delaloge et al., Ecteinascidin-743: A marine-derived compound in advanced, pretreated sarcoma patients - Preliminary evidence of activity, J CL ONCOL, 19(5), 2001, pp. 1248-1255
Authors:
Taamma, A
Misset, JL
Riofrio, M
Guzman, C
Brain, E
Lazaro, LL
Rosing, H
Jimeno, JM
Cvitkovic, E
Citation: A. Taamma et al., Phase I and pharmacokinetic study of ecteinaseidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors, J CL ONCOL, 19(5), 2001, pp. 1256-1265
Authors:
Monnet, I
Soulie, P
de Cremoux, H
Saltiel-Voisin, S
Bekradda, M
Saltiel, JC
Brain, E
Dupont-Andre, G
Cvitkovic, E
Citation: I. Monnet et al., Phase I/II study of escalating doses of vinorelbine in combination with oxaliplatin in patients with advanced non-small-cell lung cancer, J CL ONCOL, 19(2), 2001, pp. 458-463
Authors:
Laadem, A
Cvitkovic, E
Citation: A. Laadem et E. Cvitkovic, Oxaliplatin: a first DACH-platinum in oncology, B CANCER, 88, 2001, pp. S9-S13
Authors:
Bensmaine, MA
Marty, M
de Gramont, A
Brienza, S
Levi, F
Ducreux, M
Francois, E
Gamelin, E
Bleiberg, H
Cvitkovic, E
Citation: Ma. Bensmaine et al., Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients, BR J CANC, 85(4), 2001, pp. 509-517
Authors:
van Kesteren, C
Cvitkovic, E
Taamma, A
Lopez-Lazaro, L
Jimeno, JM
Guzman, C
Mathot, RAA
Schellens, JHM
Misset, JL
Brain, E
Hillebrand, MJX
Rosing, H
Beijnen, JH
Citation: C. Van Kesteren et al., Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study, CLIN CANC R, 6(12), 2000, pp. 4725-4732
Authors:
Misset, JL
Bleiberg, H
Sutherland, W
Bekradda, M
Cvitkovic, E
Citation: Jl. Misset et al., Oxaliplatin clinical activity: a review, CR R ONC H, 35(2), 2000, pp. 75-93
Authors:
Bensmaine, MA
de Gramont, A
Brienza, S
Marty, M
Levi, F
Ducreux, M
Francois, E
Gamelin, E
Bleiberg, H
Bleuzen, P
Simon, J
Cvitkovic, E
Citation: Ma. Bensmaine et al., Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/- folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients, EUR J CANC, 36(18), 2000, pp. 2335-2343
Authors:
Fizazi, K
Caliandro, R
Soulie, P
Fandi, A
Daniel, C
Bedin, A
Doubre, H
Viala, J
Rodier, JM
Trandafir, L
Le Chevalier, T
Cvitkovic, E
Armand, JP
Ruffie, P
Citation: K. Fizazi et al., Combination raltitrexed (Tomudex (R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma, EUR J CANC, 36(12), 2000, pp. 1514-1521
Authors:
Goldwasser, F
Gross-Goupil, M
Tigaud, JM
Di Palma, M
Marceau-Suissa, J
Wasserman, E
Yovine, A
Misset, JL
Cvitkovic, E
Citation: F. Goldwasser et al., Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: A phase I study in advanced gastrointestinal cancer patients, ANN ONCOL, 11(11), 2000, pp. 1463-1470
Authors:
Fandi, A
Bachouchi, M
Azli, N
Taamma, A
Boussen, H
Wibault, P
Eschwege, F
Armand, JP
Simon, J
Cvitkovic, E
Citation: A. Fandi et al., Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type, J CL ONCOL, 18(6), 2000, pp. 1324-1330
Authors:
Alexandre, J
Bleuzen, P
Bonneterre, J
Sutherland, W
Misset, JL
Guastalla, JP
Viens, P
Faivre, S
Chahine, A
Spielman, M
Bensmaine, A
Marty, M
Mahjoubi, M
Cvitkovic, E
Citation: J. Alexandre et al., Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients, J CL ONCOL, 18(3), 2000, pp. 562-573
Authors:
Delaloge, S
Laadem, A
Taamma, A
Chouaki, N
Cvitkovic, E
Pautier, P
Misset, JL
Lhomme, C
Citation: S. Delaloge et al., Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer, AM J CL ONC, 23(6), 2000, pp. 569-574
Authors:
Hasbini, A
Raymond, E
Cvitkovic, E
Eschwege, F
Armand, JP
Citation: A. Hasbini et al., Carcinomas of the nasopharynx, B CANCER, 2000, pp. 21-26
Authors:
Zeghari-Squalli, N
Raymond, E
Cvitkovic, E
Goldwasser, F
Citation: N. Zeghari-squalli et al., Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin, CLIN CANC R, 5(5), 1999, pp. 1189-1196
Authors:
Goldwasser, F
Buthaud, X
Gross, M
Bleuzen, P
Cvitkovic, E
Voinea, A
Jasmin, C
Romain, D
Misset, JL
Citation: F. Goldwasser et al., Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients, ANTI-CANC D, 10(3), 1999, pp. 263-265
Authors:
Faivre, S
Kalla, S
Cvitkovic, E
Bourdon, O
Hauteville, D
Dourte, LM
Bensmaine, MA
Itzhaki, M
Marty, M
Extra, JM
Citation: S. Faivre et al., Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: An investigator-originated compassionate-use experience, ANN ONCOL, 10(9), 1999, pp. 1125-1128
Authors:
Bekradda, M
Cvitkovic, E
Citation: M. Bekradda et E. Cvitkovic, New possibilities in chemotherapy for colorectal cancer, ANN ONCOL, 10, 1999, pp. 105-111
Authors:
Misset, JL
Dieras, V
Gruia, G
Bourgeois, H
Cvitkovic, E
Kalla, S
Bozec, L
Beuzeboc, P
Jasmin, C
Aussel, JP
Riva, A
Azli, N
Pouillart, P
Citation: Jl. Misset et al., Dose-finding study of docetaxel and doxorubicin in first-line treatment ofpatients with metastatic breast cancer, ANN ONCOL, 10(5), 1999, pp. 553-560
Authors:
Hasbini, A
Mahjoubi, R
Fandi, A
Chouaki, N
Taamma, A
Lianes, P
Cortes-Funes, H
Alonso, S
Armand, JP
Cvitkovic, E
Raymond, E
Citation: A. Hasbini et al., Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type, ANN ONCOL, 10(4), 1999, pp. 421-425
Authors:
Germann, N
Brienza, S
Rotarski, M
Emile, JF
Di Palma, M
Musset, M
Reynes, M
Soulie, P
Cvitkovic, E
Misset, JL
Citation: N. Germann et al., Preliminary results on the activity of oxaliplatin (L-OHP) in refractory recurrent non-Hodgkin's lymphoma patients, ANN ONCOL, 10(3), 1999, pp. 351-354
Authors:
Brienza, S
Bensmaine, MA
Soulie, P
Louvet, C
Gamelin, E
Francois, E
Ducreux, M
Marty, M
Andre, T
de Braud, F
Bleiberg, H
Segal, V
Itzhaki, M
Cvitkovic, E
Citation: S. Brienza et al., Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): Results from the European compassionate-use program, ANN ONCOL, 10(11), 1999, pp. 1311-1316
Authors:
Wasserman, E
Cuvier, C
Lokiec, F
Goldwasser, F
Kalla, S
Mery-Mignard, D
Ouldkaci, M
Besmaine, A
Dupont-Andre, G
Mahjoubi, M
Marty, M
Misset, JL
Cvitkovic, E
Citation: E. Wasserman et al., Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: Results of two independent phase I studies with pharmacokinetics, J CL ONCOL, 17(6), 1999, pp. 1751-1759
Authors:
Faivre, S
Raymond, E
Woyarowski, JM
Cvitkovic, E
Citation: S. Faivre et al., Supraadditive effect of 2 ',2 '-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines, CANC CHEMOT, 44(2), 1999, pp. 117-123